跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Philippines FDA
/
Kanjinti
Approved
STANDARD
Kanjinti
Amgen Technology (Ireland) Unlimited Company
🇵🇭 Food and Drug Administration - Philippines
Approval Date
Jul 14, 2025
Approval ID
bd66373f9b364333
Company
Amgen Technology (Ireland) Unlimited Company
Type
Standard
Approval Details
Approval Id
bd66373f9b364333
Drug Approval Philippines Name
Kanjinti
Product Name
Kanjinti
Registration Number
BR-1401
Brand Name
Kanjinti
Generic Name
Trastuzumab
Dosage Form
Powder For Concentrate For Solution For Infusion (IV)
Dosage Strength
150 mg
Manufacturer
Amgen Technology (Ireland) Unlimited Company
Importer
Zuellig Pharma Corporation
Distributor
Zuellig Pharma Corporation
Company Detail Path
/organization/amgen-technology-ireland-unlimited-company
Issuance Date
20 May 2022
Expiry Date
20 May 2027
Classification
Prescription Drug (RX)
Active Ingredients
Approved
Quick Info
Agency
Philippines FDA
Country
🇵🇭
Approval Date
Jul 14, 2025
Approval ID
bd66373f9b364333
Type
Standard
Back to Philippines FDA Approvals
Kanjinti - Philippines FDA Drug Approval Details